Evidence map›Paper›PMID 42830896›Full record

ArticleBrain, behavior, & immunity - health2026

Type I IFN coordinates resistance and tolerance against Zika virus disease by inducing NK cell recruitment and limiting neutrophil-driven neuropathology in the brain.

Luan Rocha Lima, Sharton Vinícius Antunes Coelho, Lana Monteiro Meuren, Yasmin Mucunã Mustafá, Emanuelle Vasconcellos de Lima, Emylle Costa-Bartuli, Elena Montes-Cobos, Ricardo Correia da Silva, Raquel Maria P Campos, Marcelo T Bozza and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luan Rocha LimaLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Sharton Vinícius Antunes CoelhoLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Lana Monteiro MeurenLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Yasmin Mucunã MustafáLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Emanuelle Vasconcellos de LimaLaboratório de Investigação em Neuroprogramação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Emylle Costa-BartuliLaboratório de Investigação em Neuroprogramação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Elena Montes-CobosLaboratório de Inflamação e Imunidade, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Ricardo Correia da SilvaLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Raquel Maria P CamposLaboratório Intermediário de Neuropatologia Experimental Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Marcelo T BozzaLaboratório de Inflamação e Imunidade, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Pedro Moreno Pimentel-CoelhoLaboratório Intermediário de Neuropatologia Experimental Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Julia R ClarkeLaboratório de Investigação em Neuroprogramação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Luciana Barros de ArrudaLaboratório de Genética e Imunologia de Infecções Virais, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zika virus (ZIKV) neurological disease arises from both direct viral cytopathic effects in the central nervous system (CNS) and host-driven neuroinflammation, with disease outcomes determined by the balance between antiviral resistance and disease tolerance. Type I interferons (IFN-I) are well-established antiviral mediators that also regulate neuroinflammation and preserve blood-brain barrier (BBB) integrity. Previous in vitro studies showed that the African-lineage ZIKV strain MR766 (ZIKV

Indexed as

Blood-brain barrierDisease toleranceNeuroinflammationType I interferonZika virus

Identifiers

PMID42830896
PMCPMC13634069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.